What's Going On With Biohaven Stock On Monday?

Benzinga_recent_news03-09

Biohaven Ltd (NYSE:BHVN) shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The movement comes in reaction to positive data from Xenon ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618678855?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-09 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618678855","market":"hk","top_or_hot":-1,"title":"What's Going On With Biohaven Stock On Monday?","media":"Benzinga_recent_news","content":"<div>\n<p>Biohaven Ltd (NYSE:BHVN) shares were trading higher on Monday during the premarket session at as high as $12.52, before falling.\nThe movement comes in reaction to positive data from Xenon ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Biohaven Stock On Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Biohaven Stock On Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 23:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven Ltd (NYSE:BHVN) shares were trading higher on Monday during the premarket session at as high as $12.52, before falling.\nThe movement comes in reaction to positive data from Xenon ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0300736062.USD","symbol_name":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday","article_id":"2618678855","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Richmond--Virginia--Usa---9-May-2019-Ill.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618678855","pubTimestamp":1773071220,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","LU0122376428.USD":"贝莱德世界能源基金A2","MPC":"马拉松原油","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0368265418.SGD":"Blackrock World Energy Fund A2 SGD-H","BK4138":"石油与天然气的炼制和营销","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","BK4588":"碎股","BK4217":"自存仓储房地产信托","XENE":"Xenon制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","SMA":"Smartstop Self Storage REIT Inc","LU0266512473.USD":"JPM GLOBAL NATURAL RESOURCES \"C\" (USD) ACC","LU0788109394.HKD":"BGF WORLD ENERGY \"A2\" (HKDHGD) ACC","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC"},"translate_title":"周一Biohaven股票会发生什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"BHVN":1,"XENE":1,"MPC":1},"content_text":"Biohaven Ltd (NYSE:BHVN) shares were trading higher on Monday during the premarket session at as high as $12.52, before falling.\nThe movement comes in reaction to positive data from Xenon Pharmaceuticals Inc.’s (NASDAQ:XENE) Phase 3 X-TOLE2 study of azetukalner in focal onset seizures.\nAzetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.\nInvestors should note that Biohaven is also developing Opakalim (BHV-7000), a selective activator of Kv7.2/7.3 potassium channels.\nThe drug candidate is currently in two phase 3 trials for focal and generalized epilepsy, and a phase 2 study for major depressive disorder.\nXenon’s study met its primary endpoint of monthly focal onset seizure frequency reduction, with a placebo-adjusted median percentage change (MPC) of -42.7% in the 25 mg group.\nIn December 2025, Biohaven reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).\nThe study did not meet its primary endpoint, a reduction of depressive symptoms as measured by change in the Montgomery Åsberg Depression Rating Scale (MADRS) over six weeks compared with placebo.\nThe stock is currently trading 12.5% below its 20-day simple moving average (SMA) and 16.7% below its 50-day SMA, indicating a bearish trend in the short term.\nOver the past 12 months, shares have decreased by 64.95%, and they are positioned closer to their 52-week lows than highs.\nThe RSI is at 36.10, which is considered neutral territory, while the MACD shows a value of -0.3294, below its signal line at -0.1633, indicating bearish pressure on the stock.\nThe combination of neutral RSI and bearish MACD suggests mixed momentum.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $30.36. Recent analyst moves include:\nTop ETF Exposure\nBHVN Price Action: Biohaven shares were up 0.10% at $9.93 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618678855","isCrawlerRequest":true}